tbuckley/cabot-search huggingface dataset:
Intergenerational transmission of child maltreatment in South Australia, 1986–2017: a retrospective cohort study
Authors: Jason M Armfield, Emmanuel S Gnanamanickam, David W Johnston, David B Preen, Derek S Brown, Ha Nguyen, Leonie Segal
Journal: The Lancet Public Health (2021)

BackgroundThe extent of intergenerational transmission of child maltreatment is unclear due to methodological limitations in previous studies. In this study, we aimed to examine factors associated with intergenerational transmission of child maltreatment and quantify its extent in a population sample over a 30-year period in South Australia.MethodsIn this retrospective cohort study, we used linked administrative data from the South Australian Birth Registry to identify dyads of mothers and their children both born in South Australia between July 1, 1986, and June 30, 2017. Three child protection system (CPS) outcomes (any CPS involvement, substantiated maltreatment, and time spent in out-of-home care) were computed from data obtained from the South Australian Department for Child Protection. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for child CPS outcomes according to their mother's CPS exposure.Findings38 556 unique mother–child dyads were included. 458 (2·0%) of 23 437 children whose mothers had no CPS involvement in childhood had a substantiated report of maltreatment and 127 (0·5%) spent time in out-of-home care. By comparison, 970 (22·1%) of 4382 children whose mothers experienced substantiated maltreatment in childhood had substantiated maltreatment and 469 (10·7%) spent time in out-of-home care. After adjusting for potential confounders, children of mothers with any CPS involvement in childhood had an increased risk of CPS contact compared with children whose mothers had no CPS involvement; this risk was greatest for children of mothers who had both substantiated maltreatment and spent time in out-of-home care (HR 6·25 [95% CI 5·59–6·98] for any CPS involvement, 13·69 [10·08–16·92] for substantiated maltreatment, and 25·78 [18·23–36·45] for any time in out-of-home care). Risks of child CPS outcomes were substantially increased for children of mothers who had a first CPS notification under the age of 1 year or who had any CPS notification at age 13–17 years.InterpretationChildren are at high risk of maltreatment if their mother experienced maltreatment as a child. Assisting survivors of childhood maltreatment, particularly female survivors, provides a crucial intervention opportunity to help prevent further child abuse and neglect.FundingAustralian National Health and Medical Research Council; Channel 7 Children's Research Foundation.
HPV Vaccination Among Young Adults in the US
Authors: Michelle M. Chen, Nicole Mott, Sarah J. Clark, Diane M. Harper, Andrew G. Shuman, Mark E. P. Prince, Lesly A. Dossett
Journal: JAMA (2021)

This study uses data from the 2010-2018 National Health Interview Survey to characterize trends in human papillomavirus (HPV) vaccination rates, ages at vaccination, and numbers of doses received among young adults in the US between 2010 and 2018.
Inconsistencies in Cutaneous Melanoma Staging Within SEER Registries
Authors: Christopher R. Cullison, David X. Zheng, Melissa A. Levoska, Jeremy S. Bordeaux, Jeffrey F. Scott
Journal: JAMA Dermatology (2021)

This cohort study explores inconsistences in cutaneous melanoma staging within the Surveillance, Epidemiology, and End Results Program registries to determine if miscoding of staging variables related to cutaneous melanoma would result in inconsistencies in final tumor staging.
When Undoing Is Not Enough — Repairing Harms Inflicted on Immigrant Children
Authors: N. Ewen Wang, Ryan Matlow, Alan Shapiro
Journal: New England Journal of Medicine (2021)

Interview with Dr. N. Ewen Wang on threats to the health and well-being of immigrant children. (10:43)Download Actions by the Biden administration to end harmful immigration policies are critically important. But solutions should also include creating conditions within the United States that will allow children exposed to immigration-related trauma to grow, learn, and thrive.
CLINICIAN EXPERIENCE WITH SPIRITUAL ASSESSMENT OF PATIENTS HAVING HEART DISEASE: POTENTIAL IMPACT OF RELIGIOUS DISTRESS ON MORTALITY
Authors: Ronald Gillilan, Martin Sherman, Anum Asif, Sameena Qawi, Gabriella Mamo, Alexandrya Weston, Rujina Munum, Thomas Pagano, Jack Long, Jill Patton, Sambhav Karki, Louise Busby, Kabir Yousuf, Carlos Ince
Journal: Journal of the American College of Cardiology (2021)
MODERATE TO HIGH DOSE OMEGA 3 SUPPLEMENTATION FOR CARDIOVASCULAR RISK REDUCTION: A SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Authors: Ahmed Elzanaty, Mahmoud Khalil, Ahmed Elballat, Omar Sajdeya, Eman Elsheikh, Sami Ghazaleh, Neha Patel, Mohammed Mhanna, Azizullah Beran, Ehab Eltahawy
Journal: Journal of the American College of Cardiology (2021)
DECADE LONG TEMPORAL TRENDS IN REVASCULARIZATION FOR PATIENTS WITH DIABETES MELLITUS: A REPORT FROM THE NORTHERN NEW ENGLAND CARDIOVASCULAR DISEASE STUDY GROUP
Authors: Jan H. Denkmann, David Malenka, Niveditta Ramkumar, Cathy Ross, Samip Vasaiwala, Michael Young, James Flynn, Michael Ferguson, Harold L. Dauerman
Journal: Journal of the American College of Cardiology (2021)
Disinfectant effectiveness against SARS-CoV-2 and influenza viruses present on human skin: model-based evaluation
Authors: Ryohei Hirose, Risa Bandou, Hiroshi Ikegaya, Naoto Watanabe, Takuma Yoshida, Tomo Daidoji, Yuji Naito, Yoshito Itoh, Takaaki Nakaya
Journal: Clinical Microbiology and Infection (2021)
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
Authors: Yichi Xu, Gendi Song, Shangdan Xie, Wenxiao Jiang, Xin Chen, Man Chu, Xiaoli Hu, Zhi-wei Wang
Journal: Molecular Therapy (2021)

Multiple studies have confirmed that programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) and immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 play pivotal roles in the treatment of numerous tumors. Patients suffering from cancer are provided hope in the form of immunotherapy. In this review, we discuss the finding that high PD-L1 expression is associated with poor clinical outcomes in prostate cancer patients. Some molecules exert their antitumor effects by downregulating PD-L1 expression in prostate cancer. Additionally, we discuss and summarize the important roles played by anti-PD-1/PD-L1 immunotherapy and its combination with other drugs, including chemotherapy and vaccines, in the treatment of prostate cancer.
Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia
Authors: Tian Tian, Lei Cao, Chuan He, Qing Ye, Ruyu Liang, Weiyan You, Huixin Zhang, Jiahuan Wu, Jinhai Ye, Bakhos A. Tannous, Jun Gao
Journal: Theranostics (2021)

Ischemic stroke remains a major cause of death, and anti-inflammatory strategies hold great promise for preventing major brain injury during reperfusion. In the past decade, stem cell-derived extracellular vesicles (EVs) have emerged as novel therapeutic effectors in immune modulation. However, the intravenous delivery of EVs into the ischemic brain remains a challenge due to poor targeting of unmodified EVs, and the costs of large-scale production of stem cell-derived EVs hinder their clinical application. Methods: EVs were isolated from a human neural progenitor cell line, and their anti-inflammatory effects were verified in vitro. To attach targeting ligands onto EVs, we generated a recombinant fusion protein containing the arginine-glycine-aspartic acid (RGD)-4C peptide (ACDCRGDCFC) fused to the phosphatidylserine (PS)-binding domains of lactadherin (C1C2), which readily self-associates onto the EV membrane. Subsequently, in a middle cerebral artery occlusion (MCAO) mouse model, the RGD-C1C2-bound EVs (RGD-EV) were intravenously injected through the tail vein, followed by fluorescence imaging and assessment of proinflammatory cytokines expression and microglia activation. Results: The neural progenitor cell-derived EVs showed intrinsic anti-inflammatory activity. The RGD-EV targeted the lesion region of the ischemic brain after intravenous administration, and resulted in a strong suppression of the inflammatory response. Furthermore, RNA sequencing revealed a set of 7 miRNAs packaged in the EVs inhibited MAPK, an inflammation related pathway. Conclusion: These results point to a rapid and easy strategy to produce targeting EVs and suggest a potential therapeutic agent for ischemic stroke.
Tejaas: reverse regression increases power for detecting trans-eQTLs
Authors: Saikat Banerjee, Franco L. Simonetti, Kira E. Detrois, Anubhav Kaphle, Raktim Mitra, Rahul Nagial, Johannes Söding
Journal: Genome biology (2021)

Abstract Trans -acting expression quantitative trait loci ( trans -eQTLs) account for ≥70 % expression heritability and could therefore facilitate uncovering mechanisms underlying the origination of complex diseases. Identifying trans -eQTLs is challenging because of small effect sizes, tissue specificity, and a severe multiple-testing burden. Tejaas predicts trans -eQTLs by performing L2-regularized “reverse” multiple regression of each SNP on all genes, aggregating evidence from many small trans -effects while being unaffected by the strong expression correlations. Combined with a novel unsupervised k-nearest neighbor method to remove confounders, Tejaas predicts 18851 unique trans -eQTLs across 49 tissues from GTEx. They are enriched in open chromatin, enhancers, and other regulatory regions. Many overlap with disease-associated SNPs, pointing to tissue-specific transcriptional regulation mechanisms.
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort
Authors: Zoé L. E. van Kempen, Eva M. M. Strijbis, Marissa M. C. T. Al, Maurice Steenhuis, Bernard M. J. Uitdehaag, Theo Rispens, Joep Killestein
Journal: JAMA Neurology (2021)

This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.
THE EFFECTS OF SLEEP APNEA ON MARKERS OF DEPRESSION IN HYPERTROPHIC CARDIOMYOPATHY
Authors: Madhav Chittimalla, Shreyas Venkataraman, Aiswarya Rajendran, Anwar Chahal, Jan Bukartyk, Naima Covassin, Shahid Karim
Journal: Journal of the American College of Cardiology (2021)
OUTCOMES OF LEFT BUNDLE BRANCH AREA PACING VERSUS RIGHT VENTRICULAR PACING: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Jian Liang Tan, Justin Lee, Vittorio Terrigno, Benjamin Saracco, Shivam Saxena, Jonathan Krathen, Yong-Mei Cha, Andrea Russo
Journal: Journal of the American College of Cardiology (2021)
Saliva and nasopharyngeal samples have similar sensitivity for detecting SARS-CoV-2
Authors: Nora M. Strong, Robert G. Badgett
Journal: Annals of Internal Medicine (2021)

Source CitationBastos ML, Perlman-Arrow S, Menzies D, Campbell JR. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021;174:501-10. https://pubmed.ncbi.nlm.nih.gov/33428446/AbstractClinical Impact RatingsGIM/FP/GP: Emergency Med: Hospitalists: Occup/Envir Health: Public Health:
Abstract 17119: Substrate Stiffness Alters Human Induced Pluripotent Stem Cell-derived Cardiomyocyte Differentiation And Maturation
Authors: Yutao Xi, Sheng-an Su, Fernanda Mesquita, Camila Hochman-Mendez, Po-Feng Lee, Shuiping So, Jianhua Gu, Jie Cheng, Luiz Sampaio, Meixiang Xiang, Doris A Taylor
Journal: Circulation (2019)

Background: Progressively increasing myocardial stiffness occurs during heart development, remodeling and aging, and plays a significant role in heart disease. The mechanisms underlying the effects...
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Rui Pei, Yin Shi, Shuhe Lv, Tingting Dai, Fengyu Zhang, Shao Liu, Bin Wu
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Nivolumab and pembrolizumab are approved for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Physicians and patients are uncertain which drug is preferable, rendering a cost-effectiveness comparison between them necessary. <h3>Objective</h3> To evaluate the cost-effectiveness of nivolumab vs pembrolizumab in treating platinum-refractory R/M HNSCC. <h3>Design, Setting, and Participants</h3> Both the network meta-analysis and cost-effectiveness analysis included patients from the CheckMate 141 and the KEYNOTE 040 phase 3 randomized clinical trials. The Checkmate 141 trial started on May 1, 2014, with the present analysis based on a September 2017 data cutoff. The KEYNOTE 040 trial started on November 17, 2014, with the present analysis based on a May 15, 2017, data cutoff. A bayesian network meta-analysis that included 856 patients was carried out, and a cost-effectiveness analysis that included 487 patients was conducted by developing a partitioned survival model, both between February and November 2020. The robustness of the model was assessed via 1-way, 2-way, and probabilistic sensitivity analyses; subgroup analyses were included; and scenario analyses were conducted to investigate the associations of dosage adjustment of nivolumab with cost-effectiveness. <h3>Main Outcomes and Measures</h3> Life-years, quality-adjusted life-years (QALYs), overall costs, and incremental cost-effectiveness ratios (ICERs) were measured. <h3>Results</h3> In the cost-effectiveness analysis that included 487 patients, for US health care payers, when nivolumab was administered based on patient weight (3 mg/kg biweekly), at a willingness-to-pay (WTP) threshold of $100 000 per QALY, the probability of nivolumab being cost-effective compared with pembrolizumab was 56%; at a WTP threshold of $150 000 per QALY, the probability was 62%. When nivolumab was administered at a fixed dose of 240 mg biweekly or 480 mg monthly, at a WTP threshold of $100 000 per QALY, the probability of nivolumab being cost-effective was 42% to 45%; at a WTP threshold of $150 000 per QALY, the probability was 52% to 55%. <h3>Conclusions and Relevance</h3> Findings from this network meta-analysis and cost-effectiveness analysis suggest considering both WTP threshold and patient body weight when choosing between nivolumab and pembrolizumab for the treatment of patients with platinum-refractory R/M HNSCC. When the WTP threshold was $100 000 per QALY, for patients weighing less than 72 kg, nivolumab (3 mg/kg, biweekly) was considered cost-effective; otherwise, pembrolizumab was preferable. When the WTP threshold was $150 000 per QALY, nivolumab (3 mg/kg biweekly) was considered cost-effective for patients weighing less than 75 kg; otherwise, fixed-dose nivolumab (240 mg biweekly or 480 mg monthly) provided more cost savings.
COARCTATION OF AORTA IS ASSOCIATED WITH LEFT VENTRICULAR STIFFNESS, LEFT ATRIAL DYSFUNCTION AND PULMONARY HYPERTENSION
Authors: Alexander C. Egbe, Janaki Devara, Likhita Shaik, Renuka Reddy Katta, Momina Iftikhar, Heidi Connolly
Journal: Journal of the American College of Cardiology (2021)
TYPE 2 MYOCARDIAL INFARCTION IN PATIENTS SELECTED FOR CORONARY ANGIOGRAPHY: ETIOLOGIES AND SURVIVAL
Authors: Viviana Zlochiver, Mohamed Hommeida, Katherine Busniewski, Hlu Vang, Mahalakshmi Angisetty, Ana Cristina Perez Moreno, Jeff Hall, Suhail Allaqaband, A. Jamil Tajik, Tanvir Bajwa, M. Fuad Jan
Journal: Journal of the American College of Cardiology (2021)
PCSK9 INHIBITOR EVOLOCUMAB REDUCES CARDIOTOXICITY OF DOXORUBICIN AND TRASTUZUMAB SEQUENTIAL TREATMENT THROUGH MYD88/NF-KB/MTORC1 PATHWAYS
Authors: Nicola Maurea, Andrea Paccone, Martina Iovine, Gerardo Botti, Fabrizio Maurea, Vincenzo Quagliariello
Journal: Journal of the American College of Cardiology (2021)
母体,新生児,小児および青年期の健康と栄養における有効な被覆率測定:進歩,将来展望,および品質健康システムに対する意味【JST・京大機械翻訳】
Authors: Marsh Andrew D, Muzigaba Moise, Diaz Theresa, Requejo Jennifer, Jackson Debra, Chou Doris, Cresswell Jenny A, Guthold Regina, Moran Allisyn C, Strong Kathleen L, Banerjee Anshu, Soucat Agnes
Journal: The Lancet Global Health (2020)
LEFT VENTRICULAR EJECTION FRACTION CATEGORIZATION IN ACUTE DECOMPENSATED HEART FAILURE: IS THIS REALLY PROGNOSTIC?
Authors: Monica Barki, Maurizio Losito, Michela Maria Caracciolo, Francesco Bandera, Marina Rovida, Eleonora Alfonzetti, Margherita Carrozzo, Marco Guazzi
Journal: Journal of the American College of Cardiology (2021)
THREE-YEAR OUTCOMES AFTER REVASUCLARIZATON IN PATIENTS WITH UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE
Authors: Kazunori Mushiake, Masanobu Ohya, Chihiro Fujii, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Kazushige Kadota
Journal: Journal of the American College of Cardiology (2021)
CATASTROPHIC MICROVASCULAR OBSTRUCTION: AN UNUSUAL CASE OF MINOCA AND CARDIOMYOPATHY IN THE ANTIPHOSPHOLIPID SYNDROME
Authors: Migdoel Cruz-Rodriguez, Amanda Doval, Paola Mercado Millan, Enrique Leal, Erica Otero-Cardenas, Jorge Ballester-Maldonado, Marcel Mesa Pabon
Journal: Journal of the American College of Cardiology (2021)
PREDICTORS OF DRUG-COATED BALLOON AND DRUG-ELUTING STENT USE IN FEMOROPOPLITEAL ENDOVASCULAR INTERVENTIONS. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE
Authors: Yulanka Castro Dominguez, Matthew Pichert, Olamide Alabi, Jiaming Huang, Ahmad Arham, Aaron Brice, Zain Ahmed, Cassius Ochoa Chaar, Poghni Peri-Okonny, Mitchel Stacy, Kim Smolderen, Carlos Mena Hurtado
Journal: Journal of the American College of Cardiology (2021)
Abstract 12649: A Faster and Safe Way to Initiate Sotalol Therapy for Patients With Atrial Fibrillation or Flutter
Authors: John Somberg, Alexander A Vinks, Min Dong, janos molnar
Journal: Circulation (2020)

Sotalol drug therapy is frequently employed to prevent the recurrence of highly symptomatic atrial fibrillation or flutter (AF, AFb). Sotalol can cause QTc prolongation that is proportional to blood concentration. Excessive concentration can cause Torsade de Pointes ventricular tachycardia (TdP). Because the risk of TdP, initiation of oral sotalol therapy is mandated by FDA to be in-hospital for a minimum of three days under ECG monitoring with facilities and personnel able to provide cardiac resuscitation. With oral administration (bid), 3 days are needed to reach maximal steady-state blood concentrations (Cmax ss) and thus maximal QTc prolongation. Three hospital days in a telemetry bed is costly and considerable expenditure of time and resources. Availability of IV sotalol makes it possible to reduce the loading time from 3 days to 1 day. The IV to oral loading regimen has been developed by model informed drug development. Serum sotalol concentrations and corresponding QTc were obtained from a previously performed bioequivalence study in healthy volunteers who received a single dose of oral and IV sotalol. NONMEM software package was used for population pharmacokinetic modeling and simulation. First Order Conditional Estimation method with Interaction (FOCE-INTER) was used for computation. We chose to administer IV sotalol over 1 hour to obtain Cmax ss target in a timeframe convenient for medical staff to supervise. The simulation for loading to the Cmax target produced by 80 mg PO bid is shown in the Figure; 60 mg IV sotalol is administered over 1 hour followed by 80 mg oral sotalol at 5 hours from start of infusion end then a second oral dose of 80 mg at 12 hours. One can target 120 mg maintenance dose by loading 90 mg IV over 1 hr followed by 120 mg oral dosing. Sotalol concentration will peak in 2-4 hours following each oral administration, thus in 21 hour there will be 3 sotalol peak concentrations. This permits evaluation of QTc response and risk of TdP all within a 1 day admission.
ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement
Authors: Laurent Faroux, Thibault Lhermusier, Flavien Vincent, Luis Nombela-Franco, Didier Tchétché, Marco Barbanti, Mohamed Abdel-Wahab, Stephan Windecker, Vincent Auffret, Diego Carter Campanha-Borges, Quentin Fischer, Erika Muñoz-Garcia, Ramiro Trillo-Nouche, Troels Jorgensen, Vicens Serra, Stefan Toggweiler, Giuseppe Tarantini, Francesco Saia, Eric Durand, Pierre Donaint, Enrique Gutierrez-Ibanes, Harindra C. Wijeysundera, Gabriela Veiga, Giuseppe Patti, Fabrizio D’Ascenzo, Raul Moreno, Christian Hengstenberg, Chekrallah Chamandi, Lluis Asmarats, Rosana Hernandez-Antolin, Joan Antoni Gomez-Hospital, Juan Gabriel Cordoba-Soriano, Uri Landes, Victor Alfonso Jimenez-Diaz, Ignacio Cruz-Gonzalez, Mohammed Nejjari, François Roubille, Éric Van Belle, German Armijo, Saifullah Siddiqui, Giuliano Costa, Sameh Elsaify, Thomas Pilgrim, Hervé le Breton, Marina Urena, Antonio Jesus Muñoz-Garcia, Lars Sondergaard, Montserrat Bach-Oller, Chiara Fraccaro, Hélène Eltchaninoff, Damien Metz, Maria Tamargo, Victor Fradejas-Sastre, Andrea Rognoni, Francesco Bruno, Georg Goliasch, Marcelo Santaló-Corcoy, Jesus Jimenez-Mazuecos, John G. Webb, Guillem Muntané-Carol, Jean-Michal Paradis, Antonio Mangieri, Henrique Barbosa Ribeiro, Francisco Campelo-Parada, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2021)
PTU-040 Daily consultant delivered ward care: effects on inpatient stay and patient care
Authors: A Rej, S Johal, M Thoufeeq
Journal: Gut (2017)

Introduction  The role of the ward round is crucial in managing inpatient care, and its importance is often neglected, as highlighted by the Royal College of Physicians (RCP)1. A daily consultant led approach was reviewed at the Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust.  Method  From November 2015, a new method of working was implemented, with a consultant of the day to review new admissions to gastroenterology, twice during the day, at 8am and 3pm, as well as performing any new emergency inpatient endoscopy. In addition to this, ward based consultants were allocated (2 luminal and 2 hepatology) to cover ward rounds daily on the new system. This was done on a rotational basis. Prior to this, consultants would review patients on the ward approximately twice a week, with a consultant reviewing new patients at 8am only, without an allocated consultant for the day. Data was retrospectively compared from April-Oct 2015, prior to implementation, to November 2015-November 2016, after implementation.  Results  Implementation of consultant of the day and ward based consultants led to a reduction in daily bed occupancy (median 83 vs 77 beds), reduced length of non-elective stay (median 7.40 vs 6.79 days), reduction in number of outliers (median 24 vs 19 inpatients), reduced monthly re-admission rate (median 3.19% vs 3.08%), greater proportion of early discharges (median 65% vs 60% stay   Conclusion  The data suggests that daily consultant ward rounds and reviews may result in reduced inpatient stay, early discharges, appropriate bed allocation and reduced complaints.  Reference  . Royal College of Physicians and Royal College of Nursing. Ward rounds in medicine: principles for best practice. London: RCP, 2012.  Disclosure of Interest  None Declared
AI ENHANCED ECG ENABLED RAPID NON-INVASIVE EXCLUSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION
Authors: Zachi Itzhak Attia, Suraj Kapa, Jennifer Dugan, Naveen Pereira, Peter Noseworthy, Francisco Lopez-Jimenez, Rickey Carter, Jessica Cruz, Daniel DeSimone, John Signorino, John Halamka, Paul Friedman
Journal: Journal of the American College of Cardiology (2021)